Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $6.1150 (0%) ($6.1150 - $6.1150) on Fri. Dec. 23, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.97% (three month average) | RSI | 17 | Latest Price | $6.1150(0%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -1.3% a day on average for past five trading days. | Weekly Trend | IOVA declines -9.1% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(40%) IWC(34%) IWO(31%) IWM(28%) IWN(25%) | Factors Impacting IOVA price | IOVA will decline at least -2.485% in a week (0% probabilities). VXX(-9%) UNG(-8%) TBT(-5%) XLU(-4%) XLRE(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.485% (StdDev 4.97%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-9.19(-250.29%) | Resistance Level | $6.6 | 5 Day Moving Average | $6.09(0.41%) | 10 Day Moving Average | $6.34(-3.55%) | 20 Day Moving Average | $6.6(-7.35%) | To recent high | -40.3% | To recent low | 2.7% | Market Cap | $895m | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |